Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study
- PMID: 10102781
- DOI: 10.1007/s002130050860
Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study
Abstract
The aim of this study was to contribute to the characterization of the entactogen (ecstasy) substance group. The psychopathological, neuroendocrine and autonomic effects of common recreational doses of the entactogen 3,4-methylenedioxyethylamphetamine (MDE), the hallucinogen psilocybin, the stimulant d-methamphetamine and placebo were investigated in a double-blind study with healthy volunteers (n = 32). Psychological effects of the drugs were assessed by means of standardized rating scales, self assessment inventories and free descriptions. The most characteristic effects of MDE were pleasant emotional experiences of relaxation, peacefulness, content and closeness to others. However, significant stimulant and hallucinogen-like effects were also present, although the latter were weaker than the effects of psilocybin. MDE elicited the strongest endocrine and autonomic effects among the three drugs, including robust rises of serum cortisol and prolactin, elevations of blood pressure and heart rate, and a moderate, but significant rise of body temperature. The apparent contrast between psychological and autonomic effects (subjective relaxation versus physical activation) was a unique feature of the MDE state. Our findings are in line with both users' reports and results from previous experimental studies, and support the view that entactogens constitute a distinct psychoactive substance class taking an intermediate position between hallucinogens and stimulants.
Similar articles
-
Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.Neuropsychopharmacology. 1999 Jun;20(6):565-81. doi: 10.1016/S0893-133X(98)00089-X. Neuropsychopharmacology. 1999. PMID: 10327426 Clinical Trial.
-
Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.Neuropsychobiology. 2002;45(4):205-12. doi: 10.1159/000063672. Neuropsychobiology. 2002. PMID: 12097810 Clinical Trial.
-
[Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?].Nervenarzt. 1996 May;67(5):369-80. Nervenarzt. 1996. PMID: 9005345 Review. German.
-
Chemistry and pharmacology of hallucinogens, entactogens and stimulants.Pharmacopsychiatry. 1998 Jul;31 Suppl 2:69-72. doi: 10.1055/s-2007-979349. Pharmacopsychiatry. 1998. PMID: 9754836 Review.
-
Neuroendocrine and cardiovascular effects of MDE in healthy volunteers.Neuropsychopharmacology. 1993 May;8(3):187-93. doi: 10.1038/npp.1993.20. Neuropsychopharmacology. 1993. PMID: 8507346 Clinical Trial.
Cited by
-
Nanowired Delivery of Mesenchymal Stem Cells with Antioxidant Compound H-290/51 Reduces Exacerbation of Methamphetamine Neurotoxicity in Hot Environment.Adv Neurobiol. 2023;32:317-352. doi: 10.1007/978-3-031-32997-5_8. Adv Neurobiol. 2023. PMID: 37480465
-
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.Ther Adv Psychopharmacol. 2023 May 29;13:20451253231172254. doi: 10.1177/20451253231172254. eCollection 2023. Ther Adv Psychopharmacol. 2023. PMID: 37284524 Free PMC article. Review.
-
Back to the Future of Neuropsychopharmacology.Adv Neurobiol. 2023;30:207-224. doi: 10.1007/978-3-031-21054-9_9. Adv Neurobiol. 2023. PMID: 36928852
-
The Altered States Database: Psychometric data from a systematic literature review.Sci Data. 2022 Nov 23;9(1):720. doi: 10.1038/s41597-022-01822-4. Sci Data. 2022. PMID: 36418335 Free PMC article.
-
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.CNS Drugs. 2022 Oct;36(10):1031-1047. doi: 10.1007/s40263-022-00944-y. Epub 2022 Sep 12. CNS Drugs. 2022. PMID: 36097251 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources